Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Front Immunol ; 11: 345, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32194563

RESUMEN

The palladacycle complex DPPE 1.2 was previously shown to inhibit Leishmania (Leishmania) amazonensis infection in vitro and in vivo. The present study aimed to evaluate the effect of DPPE 1.2 associated with a recombinant cysteine proteinase, rLdccys1, and the adjuvant Propionibacterium acnes on L. (L.) amazonensis infection in two mouse strains, BALB/c, and C57BL/6. Treatment with this association potentiated the leishmanicidal effect of DPPE 1.2 resulting in a reduction of parasite load in both strains of mice which was higher compared to that found in groups treated with either DPPE 1.2 alone or associated with P. acnes or rLdccys1. The reduction of parasite load in both mice strains was followed by immunomodulation mediated by an increase of memory CD4+ and CD8+ T lymphocytes, IFN-γ levels and reduction of active TGF-ß in treated animals. No infection relapse was observed 1 month after the end of treatment in mice which received DPPE 1.2 associated with rLdccys1 or rLdccys1 plus P. acnes in comparison to that exhibited by animals treated with DPPE 1.2 alone. Evaluation of serum levels of AST, ALT, urea, and creatinine showed no alterations among treated groups, indicating that this treatment schedule did not induce hepato or nephrotoxicity. These data indicate the potential use of this association as a therapeutic alternative for cutaneous leishmaniasis caused by L. (L) amazonensis.


Asunto(s)
Antiprotozoarios/uso terapéutico , Cisteína Endopeptidasas/uso terapéutico , Inmunoterapia/métodos , Leishmaniasis Cutánea/tratamiento farmacológico , Propionibacterium acnes , Proteínas Protozoarias/uso terapéutico , Animales , Antiprotozoarios/administración & dosificación , Antiprotozoarios/toxicidad , Terapia Combinada , Cisteína Endopeptidasas/administración & dosificación , Cisteína Endopeptidasas/inmunología , Cisteína Endopeptidasas/toxicidad , Evaluación Preclínica de Medicamentos , Femenino , Memoria Inmunológica , Interferón gamma/metabolismo , Leishmania mexicana , Leishmaniasis Cutánea/inmunología , Ganglios Linfáticos/inmunología , Activación de Linfocitos/efectos de los fármacos , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Proteínas Protozoarias/administración & dosificación , Proteínas Protozoarias/inmunología , Proteínas Protozoarias/toxicidad , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/inmunología , Proteínas Recombinantes/uso terapéutico , Proteínas Recombinantes/toxicidad , Subgrupos de Linfocitos T/inmunología , Factor de Crecimiento Transformador beta/metabolismo
2.
J Med Food ; 14(6): 557-62, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21554130

RESUMEN

The infections by protozoans of the genus Leishmania are a major worldwide health problem, with high endemicity in developing countries. The drugs of choice for the treatment of leishmaniasis are the pentavalent antimonials, which cause renal and cardiac toxicity. As part of a search for new drugs against leishmaniasis, we evaluated the in vitro Leishmania protease inhibition activity of extracts (hexanic, ethyl-acetate, and ethanolic) and fukugetin, a bioflavonoid purified from the ethyl-acetate extract of the pericarp of the fruit of Garcinia brasiliensis, a tree native to Brazilian forests. The isolated compound was characterized by using spectral analyses with nuclear magnetic resonance, mass spectroscopy, ultraviolet, and infrared techniques. The ethyl-acetate extract and the compound fukugetin showed significant activity as inhibitors of Leishmania's proteases, with mean (±SD) IC(50) (50% inhibition concentration of protease activity) values of 15.0±1.3 µg/mL and 3.2±0.5 µM/mL, respectively, characterizing a bioguided assay. In addition, this isolated compound showed no activity against promastigote and amastigote forms of L. (L.) amazonensis and mammalian cells. These results suggest that fukugetin is a potent protease inhibitor of L. (L.) amazonensis and does not cause toxicity in mammalian or Leishmania cells in vitro. This study provides new perspectives on the development of novel drugs that have leishmanicidal activity obtained from natural products and that target the parasite's proteases.


Asunto(s)
Antiprotozoarios/farmacología , Garcinia/química , Leishmania/efectos de los fármacos , Leishmania/enzimología , Extractos Vegetales/farmacología , Inhibidores de Proteasas/farmacología , Proteínas Protozoarias/antagonistas & inhibidores , Animales , Brasil , Frutas/química , Humanos , Concentración 50 Inhibidora , Leishmaniasis/parasitología , Péptido Hidrolasas/metabolismo , Proteínas Protozoarias/metabolismo , Ratas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA